GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (FRA:CPH) » Definitions » Short Percentage of Float

Histogen (FRA:CPH) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is Histogen Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Histogen's Short Percentage of Float

For the Biotechnology subindustry, Histogen's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Histogen's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Histogen's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Histogen's Short Percentage of Float falls into.


Histogen (FRA:CPH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (FRA:CPH) » Definitions » Short Percentage of Float
Comparable Companies
GLMD BLCM NBY CYTO RUBY AGTX CFRX ADTX NTRR ISCO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
HSTO:USA
Address
10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
Website
https://www.histogen.com
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Histogen (FRA:CPH) Headlines

No Headlines